SCHEMBL17550869

SCHEMBL17550869

COC1=CCN=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13620726 0.62
SCHEMBL20267202 0.57
SCHEMBL2048133 0.54
SCHEMBL7068841 0.54
SCHEMBL1145502 0.51
SCHEMBL8265788 0.49 CYP3A4 (0.35)
SCHEMBL353814 0.45 NNMT (0.54)
SCHEMBL1276533 0.41 CYP3A4 (0.59)
1,4-Dimethoxybenzene SCHEMBL21802643 0.41 CA1 (1.00)
1,4-Dimethoxybenzene SCHEMBL8489 0.41 CA1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
EP-2343069-B1 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME (US) 2016-03-02 EP disclosed
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2015-09-24 US disclosed
US-9073871-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-07-07 US disclosed
US-20140371467-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2014-12-18 US disclosed
US-8859591-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-10-14 US disclosed
US-20130296355-A1 GLUCAGON RECEPTOR MODULATORS PFIZER (US) 2013-11-07 US disclosed
US-8507533-B2 Glucagon receptor modulators PFIZER INC. (US) 2013-08-13 US disclosed
US-20120202834-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-08-09 US disclosed